Abstract:214 Background: In prior studies, the efficacy and safety of selpercatinib, a selective RET inhibitor, was consistent in RET+ NSCLC pts across geographies. As previously reported, LIBRETTO-431 met its primary endpoint of improved PFS by blinded independent central review (BICR) at the pre-planned interim analysis. Here we report the efficacy and safety from LIBRETTO-431 in pts from East Asia, a majority of the study population. Methods: LIBRETTO-431 (NCT04194944) is a randomized, open-label phase 3 trial comparing 1L selpercatinib vs control (platinum/pemetrexed +/- pembrolizumab). Geography (East Asia vs non-East Asia) was a stratification factor. BICR-assessed PFS, ORR and DOR were examined in pts from East Asia randomized with investigator’s intent to treat with pembrolizumab (ITT-pembro) if assigned to control. AE data were collected for all pts from East Asia who received at least one dose of selpercatinib or control (n=140). Results: Of 142 randomized pts from East Asia, 116 were included in the ITT-pembro population (selpercatinib: n=75, control: n=41). Baseline characteristics were well balanced, however the selpercatinib arm had slightly more pts from East Asia vs the control arm (58% vs 49%). In ITT-pembro pts from East Asia, with a median follow up of 19.4 mo and 21.2 mo in the selpercatinib and control arms respectively, the median PFS was not yet reached with selpercatinib (95% CI: 16.4-NE) vs 11.1 mo (95% CI: 7.0-16.8) with control. At 12 mo the PFS rate was 72.8% with selpercatinib vs. 41.7% with control. The ORR was 86.7% (95% CI: 76.8-93.4) with selpercatinib vs 61.0% (95% CI: 44.5-75.8) with control. Similar results were observed in pts from East Asia in the overall ITT population. The most common AEs reported in pts from East Asia on selpercatinib included elevated AST (73.6%), elevated ALT (70.3%), hypertension (60.4%), increased blood bilirubin (52.7%) and diarrhea (44.0%) while those reported with control included anemia (61.2%), elevated AST (49.0%), leukopenia (49.0%), neutropenia (44.9%) and elevated ALT (42.9%). A summary of safety data for selpercatinib vs control in pts from East Asia is presented in the table. Conclusions: LIBRETTO-431 is the first randomized study to report efficacy and safety of a RET inhibitor in pts from East Asia. Consistent with the results in the overall population, selpercatinib demonstrated superior PFS compared to chemotherapy + pembrolizumab in 1L pts from East Asia. These data support early comprehensive genomic testing and the use of selpercatinib as the preferred 1L regimen in RET+ NSCLC pts across geographies. Clinical trial information: NCT04194944 . [Table: see text]

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET Fusion-Positive Non-Small-cell Lung Cancer: a Phase II Clinical Trial (LIBRETTO-321).

Intracranial Outcomes of 1L Selpercatinib in Advanced RET Fusion-Positive NSCLC: LIBRETTO-431 Study.

1413Tip LIBRETTO-431: Selpercatinib in Treatment (Tx)-Naïve Patients with RET Fusion-Positive (RET+) Non-Small Cell Lung Cancer (NSCLC)

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).

Efficacy and Safety of 1L Selpercatinib in RET Fusion-Positive NSCLC: LIBRETTO-431 East Asian Subgroup Analysis.

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer

Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer

Selpercatinib Monotherapy in a Chinese Patient with RET Fusion/ EGFR Co-Mutated Nonsmall Cell Lung Cancer from the Phase II LIBRETTO-321 Study: a Case Report.

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.

Health-related Quality of Life (hrqol) and Symptoms in LIBRETTO-431 Patients with RET Fusion-Positive Advanced Non-Small-cell Lung Cancer (NSCLC).

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET-altered Thyroid Cancers: Results from the Phase II LIBRETTO-321 Study

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Selpercatinib or Chemotherapy in <i>RET</i> Fusion-Positive NSCLC

Clinical Activity of Selpercatinib in RET -mutant Pheochromocytoma

LIBRETTO-531: a Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET-mutant Medullary Thyroid Cancer

Patient-reported outcomes with selpercatinib treatment in patients with RET -driven cancers in the phase I/II LIBRETTO-001 trial☆